Literature DB >> 35575736

Implant Insertion Procedure of the Port Delivery System With Ranibizumab: Overview and Clinical Pearls.

Dante J Pieramici, Mark R Wieland, Jay M Stewart, Robert T Chang, Shamika A Gune, Varun K Malhotra, Giulio Barteselli, Carl C Awh.   

Abstract

OBJECTIVE: To describe the Port Delivery System with ranibizumab implant insertion procedure.
METHODS: A surgical procedure based on the clinical trial program in patients with retinal diseases.
RESULTS: An infusion line is placed in the infero-temporal quadrant; a superotemporal quadrant corneal traction suture is recommended. The superotemporal quadrant peritomy of 6 × 6 mm is executed with gentle, purposeful tissue handling. Generous posterior and lateral sub-Tenon's capsule dissection creates laxity for the subsequent closure. Adequate scleral hemostasis is achieved with wet-field cautery to maintain a clean field. The implant is filled under magnification with a customized formulation of ranibizumab. A precise 3.5-mm-long scleral incision (4 mm posterior and parallel to the limbus) is created to ensure proper implant fit. The exposed pars plana undergoes laser ablation to reduce vitreous hemorrhage risk. A pars plana incision is made, and the implant is inserted perpendicular to the globe and seated flush against the sclera. Complete closure of both the conjunctiva and Tenon's capsule with scleral anchoring and mild tissue overhang at the anterior limbus is performed to reduce conjunctival erosion and retraction risks.
CONCLUSION: The procedure is straightforward yet requires precise preoperative and intraoperative preparation and standardized surgical techniques. [Ophthalmic Surg Lasers Imaging Retina. 2022;53:249-256.].

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35575736     DOI: 10.3928/23258160-20220408-01

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  1 in total

Review 1.  Ranibizumab port delivery system: a clinical perspective.

Authors:  David A Eichenbaum; Abrahim Ahmed; Farhan Hiya
Journal:  BMJ Open Ophthalmol       Date:  2022-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.